Research Network Investigators

Michael J. Rybak, Pharm.D., M.P.H.
Professor of Pharmacy and Medicine

Click here for Biographical Sketch:

Education / Training :

Northeastern University, Boston MAB.S. Pharm.1979Pharmacy
Wayne State University, Detroit, MIPharm.D.1981Clinical Pharmacy
Wayne State University, Detroit, MIM.P.H.2005Public Health

Personal Statement:

For the past 30 years my research has focused on the optimization of antibiotic therapy, predominately in the area of gram-positive bacteria. The emphasis of my work has been associated with methicillin-resistant S. aureus, multi-drug resistant enterococci and streptococci with over 245 publications including research papers, reviews and editorials devoted to these organisms as listed in PubMed. Although my initial research focused on the pharmacokinetics and drug adjustment required to optimize the treatment of infections caused by these organisms, over the last 15 years I have focused more on the development of resistance secondary to antibiotic exposure. The ultimate goal of the work carried out in my laboratory is to understand the relationships between drug pharmacokinetics and pharmacodynamics (PK/PD) and the development of resistance. To accomplish these goals we have developed and validated a variety of in vitro PK/PD models that allow us to expose bacterial pathogens to antimicrobials precisely simulating human pharmacokinetic drug concentrations. An example of these PK/PD models include a simulated endocardial vegetation model that was validated against six endocarditis rabbit models of infection. The development and validation of this model was funded by the Proctor and Gamble Animal Alternative Research Award program. To obtain the necessary expertise in microbiology and molecular techniques I have completed research sabbaticals and have learned basic and advanced laboratory procedures from the faculty of the division of Infectious Diseases at Wayne State University (WSU). I have also completed graduate coursework in molecular biology, immunology and bacterial pathogenesis from the immunology and microbiology department at the School of Medicine at WSU. Our group routinely performs PK/PD modeling experiments, analytical drug assays, drug susceptibility testing, bacterial resistance population analysis, biofilm quantification studies, and a variety of molecular techniques including PFGE, multiplex PCR, qRT-PCR and other techniques required to investigate resistance mechanisms. Our research program is currently funded via an NIH R21, an NIH contract (Co-Inv.), a Michigan Public Health Department grant and various pharmaceutical industry contracts and investigator initiated grants. Therefore, we are uniquely qualified and capable to cover the scope of the proposed work and contribute to the understanding of antimicrobial exposure and the development and prevention of resistance.

Positions and Employment:

7/81 - 5/87Assistant Professor of Pharmacy Practice, Wayne State University (WSU)
7/85 - Present Director, Research Fellowship in Infectious Diseases Pharmacotherapy, WSU
5/87 - 5/93Associate Professor of Pharmacy Practice, WSU
8/88 - 8/95Associate Professor of Medicine (Adjunct), Division of Infectious Diseases, WSU
6/90 - PresentDirector, Anti-Infective Research Laboratory, College of Pharmacy, Wayne State University
5/93 - PresentProfessor of Pharmacy Practice, Wayne State University College of Pharmacy
7/93 - 7/03Director of Research & Education, Department of Pharmacy, Detroit Receiving Hospital
8/95 - PresentField Editor, Infectious Diseases, Pharmacotherapy
8/95 - Present Professor of Medicine (Adjunct), Department of Internal Medicine, WSU
10/03 – 11/11 Associate Dean of Research, College Pharmacy & Health Sciences, WSU


1990The Upjohn Pharmacy Research Award - Michigan Society of Hospital Pharmacists
1990Merck Foundation Fellowship Award
1991American College of Clinical Pharmacy Fellow Recognition Award
1991Wayne State University Academic Achievement Award for Natural Sciences
1992R.W. Johnson Research Institute Fellowship Award
1992Wayne State University Career Chair Development Award
1996Fellow, Infectious Diseases Society of America
1997Distinguished Faculty Fellowship Award, Wayne State University
2000Impact paper Research Award, Society of Infectious Disease Pharmacists
2003American Society of Health-System Pharmacists, Award for Sustained Literature Contributions to the Pharmacy Literature for ASHP
2003Ted Goldberg Prize in Community Health, Wayne State University School of Medicine
2004American College of Pharmacy Russell Miller Award for Sustained Literature Contributions
2011Lead Industry Research Award, Wayne State University
2011 Research Recognition Award, Outstanding Achievements in Clinical Sciences Research, Wayne State University

Selected peer-reviewed publications (in chronological order)
(Publications selected from 265 peer-reviewed publications)

  1. Parra-Ruiz J., Vidaillac C., Rose W.E., Rybak MJ. Activities of high-dose daptomycin, vancomycin, and moxifloxacin aong or in comibination with clarithromycin or rifampin in a novel in vitro model of staphylococcus aureus biofilm. Antimicrob Agents Chemother. 2010 Oct; 54(10): 4329–4334.
  2. Steed ME, Vidaillac C, Rose WE, Winterfield P, Rybak MJ. Characterizing vancomycin resistant Enterococcus (VRE) strains with varying daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy. 2011 Oct; 55(10): 4748-4754.
  3. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of Standard and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus in a simulated endocardial vegetations (SEV) in vitro Pharmacokinetic/Pharmacodynamic model. Antimicrob Agents Chemother. 2012 Jun;56(6):3174-80.
  4. Steed ME, Vidaillac C, Winterfield P, Biek D, Rybak MJ. Evaluation of ceftaroline activity versus ceftriaxone against clinical isolates of Streptococcus pneumonia with various susceptibilities to cephalosporins in an in vitro pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother. 2012 May;56(5)2691-5.
  5. Hall AD, Steed ME, Arias CA, Murray BE, Rybak MJ. Evaluation of standard and high-dose daptomycin versus linezolid against vacomycin-resistant Enterococcus isolates in an in vitro pharmacokinetic/pharmacodynamics model with simulated endocardial vegetations. Antimicrob Agents Chemother. 2012 Jun;56(6):3174-80
  6. Hayakawa K, Marchaim D, Pogue JM, Ho K, Parveen S, Nanjireddy P, Sunkara B, Singla M, Jagadeesh KK, Moshos JA, Bommarito S, Mroue R, Farhat M, Obeid T, Chaudhry A, Vadlamudi G, Lephart PR, Martin ET, Rybak MJ, Kaye KS. Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus a case-case-control study. American Journal of Infection Control. 40(2012):261-3.
  7. Avery LM, Steed ME, Woodruff AE, Hasan M, Rybak MJ. Daptomycin non-susceptible (DNS) Vancomycin intermediate Staphylococcus aureus (VISA) Vertebal Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole. Antimicrob Agents Chemother. 2012 Nov;56(11):5990-3.
  8. Levy DT, Steed ME, Rybak MJ, Guo Y, Gialanella P, Hanau L, Muggia V, Ostrowsky B. Successful treatment of a left ventricular assist device infection with daptomycin non-susceptible methicillin-resistant Staphylococcus aureus: case report and review of literature. Transpl Infect Dis. 2012 Oct;14 (5):E89-96.
  9. Steed ME, Werth BJ, Ireland CE, Rybak MJ. Evaluation of the novel combination of high dose daptomycin plus trimethoprim/sulfamethoxazole against daptomycin non-susceptible (DNS) methicillin-resistant Staphylococcus aureus (MRSA) using an in vitro PK/PD model of simulated endocardial vegetations. Antimicrob Agents Chemother. 2012 Nov;56(11):5709-14.
  10. Hayakawa K, Marchaim D, Palla M, Gudur UM, Pulluru H, Bathina P, Alshabani K, Govindavarjhulla A, Mallad A, Abbadi DR, Chowdary D, Kakarlapudi H, Guddati H, Das M, Kannekanti N, Vemuri P, Doddamani R, Rakesh Mundra VR, Guddeti RR, Policherla R, Bai S, Lohithaswa S, Shashidharan SP, Chidurala S, Diviti S, Sukayogula K, Jjoseph M, Pogue JM, Lephart PR, Martin ET, Rybak MJ, Kaye KS. Epidemiology of vancomycin-resistant Enterococcus faecalis; a case-case-control study. Antimicrob Agents Chemother. 2012 Oct 15 [Epub ahead of print].
  11. Werth BJ, Sakoulas G, Rose WE, Pogliano J, Tewhey R, Rybak MJ. Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin nonsusceptible vancomycin-intermediate staphylococcus aureus in a pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother. 2012 Oct 15. [Epub ahead of print].
  12. Judge T, Pogue JM, Marchaim D, Ho K, Kamatam S, Parveen S, Tiwari N, Nanjireddy P, Bheemreddy S, Biedron C, Reddy SM, Khammam V, Chalana IK, Tumma RS, Collins V, Yousuf A, Lephart PR, Martin ET, Rybak MJ, Kaye KS, Hayakawa K. Epidemiology of vancomycin-resistant enterococci with reduced susceptibility to daptomycin. Infect Control Hosp Epidemiol. 2012 Dec;33(12):1250-4.

Research Support
Ongoing Projects
Independent Investigator Initiated Research Grants:

  1. NIH (R211AI092055-02, 9/30/11-8/31/12)
    The overall objective of this study is to define the dose of exposure breakpoint (pharmacokinetic/pharmacodynamic [PK/PD breakpoint] for daptomycin and the correlating dose and determine if known phenotypic and genotypic changes associated with daptomycin resistance in S. aureus Is also found in enterococci.
    Role: PI
  2. Michigan Department of Community Health (11/1/12- 7/31/12)
    The project is part of the Centers for Disease Control and Prevention’s efforts to create a mechanism to facilitate the reporting and analyzing antimicrobial use and the development of resistance created through the National Healthcare Safety Network. The objective of this project is to facilitate risk-adjusted inter- and intra facility benchmarking of antimicrobial use for the Detroit Medical Center and the Unversity of Michigan Hospitals.
    Role: PI
  3. Forest Pharmaceuticals (4/1/12- 3/31/14)
    The objective of this study is to evaluate the impact of ceftaroline fosamil treatment versus that of vancomycin for MRSA acute bacterial skin and soft tissue infections in a randomized clinical trial. The primary and secondary objectives are early clinical response and econimic outcomes of the patients at the end of therapy.
    Role: PI
  4. NIH (HHSN272201000039C, 9/24/10-9/23/15)
    Targeted Clinical Trials to Reduce the Risk of Antimicrobial Resistance: Antimicrobial Therapy of multi-drug Resistant Acinetobacter baummannii.
    Major Goals: This contract with the NIH supports a multi-center clinical trial studying the antimicrobial therapy of extremely-drug resistant Gram-negative bacilli.
    Role: Co-Inv
  5. (Cubist Pharmaceuticals. 11/05/10 – 05/31/12)
    Evaluation of high dose daptomycin versus vancomycin, both alone or combined with clarithromycin and rifampin against isolates of Staphylococcus aureus and S. epidermidis in a novel in vitro PK/PD model of bacterial biofilm.
    Major goals:The objective of the present study will be to evaluate the activity of daptomycin alone or in combinations with rifampin and clarithromycin agasint strains of S. aureus and S. epidermidis with varying susceptiblitiy profiles (MRSA, hVISA, MRSE) grown in biofilm on titanium, steel and teflon coupons.
    Role: PI
  6. (Clinical Therapeutics. 12/12/11 – 3/12/12)
    Effect of DNase in combination with vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and methicillin-susceptible strain biofilm in an in vitro simulated endocardial vegetation model.
    Major Goals: Determine the impact of DNase in combination with vancomycin and daptomycin on biofilm embedded methicillin-resistant S. aureus.
    Role: PI
  7. (Forest Pharmaceuticals. 12/16/11 – 8/30/12)
    A preliminary evaluation of the activity of ceftaroline alone, or in combination with daptomycin or vancomycin against an isogenic MRSA/VISA pair in a one-compartment PK/PD model.
    Major Goals: Evaluate the impact of ceftaroline on enhancing the bactericidal activity of daptomycin on MRSA/VISA strains pairs.
    Role: PI
  8. (Cubist Pharmaceuticals. 8/2/11 – 8/1/12)
    Evaluation of standard and high-dose daptomycin versus linezolid against Enterococcus in a simulated endocardial vegetation in vitro model.
    Major Goals: Evaluate the dose exposure of high-dose daptomycin against multi-drug resistant enterococci including vancomycin and linezolid resistant strains.
    Role: PI
  9. (Forest Pharmaceuticals. 12/9/11 – 11/30/14)
    Clinical and Economic outcomes of Ceftaroline fosamil for the treatment of acute baceterial skin and skin structure infections with documented or suspected themicillin-resistant Staphylococcus aureus.
    Major Goals: Determine the efficacy and pharmacoencomic impact of ceftaroline vs. vancomycin for skin and skin structure infections.
    Role: PI
  10. (Cerexa Pharmaceuticals. 6/12/12 – 6/11/13)
    Evaluation of ceftaroline plus avibactam against common pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamics model.
    Major Goals: Evaluate the impact of the non-beta lactam beta-lactamase inhibitor on common anaerobic pathogens in an in vitro PK/PD model.
  11. (Forest Pharmaceuticals. 6/4/12 – 5/31/15)
    Evaluation of a ceftaroline plus daptomycin de-escalation protocol against an isogenic MRSA/VISA pair in a hollow-fiber pharmacokinetic/pharmacodynamics model.
    Major Goals: Determine the feasibility of a daptomycin/ceftaroline combination de-escalation to monotherapy scheme against MRSA/VISA isolates in an in vitro PK/PD model.
    Role: PI
  12. (Cerexa Pharmaceuticals. Pending)
    Ceftaroline alone and in combination with amikacin in an in vitro pharmacodynamics model, simultaneously inoculated with methicillin-resistant S. aureus and E. coli.
    Major Goals: Evaluate the activity of ceftaroline alone and in combination with amikacin against simultaneous E.coli and methicillin-resistant S. aureus.
    Role: PI

Debra A. Goff
Clinical Associate Professor
Click here for Biographical Sketch:

Education / Training :

University of Illinois at ChicagoB.S.1976-80Pharmacy
University of Illinois at ChicagoPharm.D.1980-82Pharmacy
Clinical Pharmacy
University of Illinois at Chicago1982-83Residency

Positions and Employment:

1983-89 Clinical Pharmacist Family Practice Grant Medical Center
1989-2009 Clinical Associate Professor College of Pharmacy The Ohio State University
1989-2009Infectious Diseases Specialist Department of Pharmacy The Ohio State University Medical Center
2001-2012Program Director Infectious Disease Residency

Professional Activities:

2008-2013Board Member, National Foundation for Infectious Diseases
2011-currentBoard Member, Making a Difference Infectious Diseases
2012-currentBoard Member and Advisor to Federation of Infectious Diseases Society South Africa (FIDSSA)
International Advisor for Antimicrobial Stewardship
1995-currentReviewer for Pharmacotherapy, Clinical Infectious Diseases, Antimicrobial Agents Chemotherapy,
Infection Control Hospital Epidemiology, Annals of Pharmacotherapy
1989-currentAbstract reviewer, American College of Clinical Pharmacy
2003-2005Society of Infectious Diseases Pharmacist, Annual Report committee
1997-2001Pharmacoeconomics: Infectious Diseases, Editorial Board
1996Society of Infectious Diseases Pharmacist, Elections committee
1984-89Pharm.D. Committee member, Ohio State University


2006Fellow of the American College of Clinical Pharmacy
2002 OSUMC Leadership Council for Clinical Value Enhancement for developing the “Community-Acquired Pneumonia in Immunocompetent Adult Patients” Clinical Practice Guideline
1985Teaching Award: American Academy of Family Physicians
1986Teaching Award: American Academy of Family Physicians
1988Teaching Award: American Academy of Family Physicians

Selected peer-reviewed publications:

  1. Goff D.A., Koletar S.L., Buesching W.J., Barnishan J, Fass R.J. Isolation of fluconazole resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles. Clin Inf Dis. 1995;20:77-83.
  2. Fass R.J., Goff D.A. Sierawski S. Candida infections in the surgical intensive care unit. J Antimicrob Chemother 1996; 38;915-6.
  3. Goff D.A., Sierawski S. Fass R.J. Cost analysis of Candida infection among surgical intensive care unit patients. Clin Drug Invest 1996 12(4) 176-180.
  4. McKinnon PS., Goff DA., Kern JW., et al. Temporal relationship between Candida risk factors in the surgical intensive care unit. Arch Surg. 2001;136:1401-1409.
  5. Potoski BA. Mangino J., Goff DA. Clinical failure of linezolid and implications for the clinical microbiology laboratory. Emerg Inf Dis 2002;8:12:1519-20.
  6. Goff D.A., Sierawski S.J. Clinical experience with quinupristin/dalfopristin for the treatment of antimicrobial-resistant gram-positive infections. Pharmacotherapy 2002;22(6).
  7. Schafer J, Goff, DA, Stevenson K, Mangino JE. Early experience with Tigecycline for ventilator associated pneumonia and bacteremia caused by multi-drug resistant Acinetobacter baumannii. Pharmacotherapy 2007.
  8. Goff DA, Dowzicky MJ., Prevalence and regional variation in methicillin-resistant Staphylococcus aureus (MRSA) in the USA and comparative in vitro activity of tigecycline, a glycylcycline antimicrobial. J Med Micro 2007 56: 1-7.
  9. Schafer J, Goff D., Mangino Doripenem: A new addition to the carbapenem class of antimicrobials Recent Patents Anti Inf Drug Discovery 2009 4(1):1-11.
  10. Goff DA., Mangino JE., Ertapenem: No effect on aerobic gram-negative susceptibilities to imipenem. J Infection 2008 57:123-7.
  11. Bazan JA, Bauer KA, Hollister AS, Mangino JE, Shidham G, Firstenberg MS, Reed EE, Goff DA. Pharmacokinetic Monitoring of Peramivir in Two Critically Ill Patients with 2009 H1N1 Influenza A Requiring Continuous Renal Replacement Therapy. Pharmacotherapy 2010;30(10):1016–1020
  12. Goff DA. Challenges of Antimicrobial Stewardship Programs: What’s a Steward to Do? Inf Dis Clin Practice 2011 19(6):375
  13. Winters H., Parbhoo R., Schafer J., Goff D.A. Extended-Spectrum B-Lactamase–Producing Bacterial Infections in Adult Solid Organ Transplant Recipients. Ann Pharmacother 2011;45(3) 309-316.
  14. Goff DA Antimicrobial stewardship: bridging the gap between quality care and cost. Curr Opin in Infect Dis 2011,24 (suppl 1):S11–S20.
  15. Goff DA., Jankowski C. Tenover FC. Using rapid diagnostic tests to optimize Antimicrobial Selection in Antimicrobial Stewardship Programs Pharmacotherapy 2012; 32(8) 677-687
  16. Goff DA., Bauer K., Mangino JE. Antimicrobial Stewardship; Beyond just the costs. Infectious Disease Special Edition. 2012. McMahon Publishing Group, New York, NY.
  17. Goff DA. iPhones, iPads, and Medical Applications for Antimicrobial Stewardship Pharmacotherapy 2012 32(7) 657-661.
  18. Goff DA. Bauer KA., Reed E., Stevenson KB., Taylor JJ., West JE. Is the “Low-Hanging Fruit” Worth Picking for Antimicrobial Stewardship Programs? 2012 Clin Inf Dis Invited Article 55(4):587-92.
  19. Jankowski C. Balada-Llasat J. Raczkowski M., Pancholi P., Goff DA. A Stewardship Approach to Combating Multidrug-Resistant Acinetobacter baumannii Infections with Minocycline Inf Dis Clin Practice 2012 20(3) 184-187.
  20. Stevenson KB, Balada-Llasat JM, Bauer K, Goff DA. et al. The Economics of Antimicrobial Stewardship: The Current State of the Art and Applying the Business Case Model. Infect Control Hosp Epidemiol 2012; 33 (4) 389-397.
  21. 21. Nicolau D., Carmeli Y. , Crank CW., Goff DA, Graber C., Lima A.,, Goldstein E. Carbapenem stewardship: Does ertapenem affect Pseudomonas susceptibility to other carbapenems? A review of the evidence. International J Antimicrob Agents 2012 39; 11– 15

Research Support:

  • An Antimicrobial stewardship program’s approach to patients transitioning from hospital to home on outpatient parenteral antimicrobial therapy. Sponsor Merck PI Goff DA.
  • Retrospective investigation of the comparative effectiveness of Daptomycin vs Vancomycin for the treatment of MRSA bacteremia with Vancomycin MICs of 1.5-2mcg/ml. A multicenter study Sponsor Cubist CO-PI Goff DA, Bauer K.


  • iPad/iPhone Medical “app” STAB-IT (S. aureus bacteremia is terrible) funded $38,000 by OSUMC College of Medicine
  • Higher dose daptomycin for Enterococcal infections. A multicenter study PI M. Rybak Wayne State University


  • A case-control matched study of risk factors and outcomes of patients with carbapenemase producing Enterobacteriaceae Sponsor Merck PI D. Goff


  • Clinical Impact of the Cepheid® GeneXpert Rapid Polymerase Chain Reaction for Detection of Staphylococcusaureus or Methicillin-Resistant Staphylococcus aureus . Sponsor Cepheid PI Goff DA


  • Ertapenem’s Effect On Pseudomonas Aeruginosa and Other Gram Negative Susceptibility To Imipenem Sponsor Merck PI: D. Goff


  • Redefining the role of antifungal therapy in acute leukemia and bone marrow transplant patients.
    PI: D. Goff


  • Clinical outcome of patients with ESBL K. pneumoniae or E. coli. Sponsor Merck PI: D. Goff

John A. Bosso
Professor of Clinical Pharmacy and Medicine
Click here for Biographical Sketch:
Education / Training :
SUNY at BuffaloBS05/1970Pharmacy
SUNY at BuffaloPharm.D.07/1973Clinical Pharmacy

Personal Statement:

Over my career, my research has focused on antimicrobial pharmacokinetics and efficacy while occasionally encompassing antimicrobial use issues of direct clinical relevance. This work has focused on the pharmacokinetics of newer antibiotics in special populations and applied pharmacodynamics with both in vitro and in vivo experimentation. The relationship between patterns of antimicrobial utilization at the institutional level and changing susceptibility patterns has been a common thread in our studies. Of late, this work has been enhanced by use of sophisticated statistical modeling techniques including time-series analysis which has allowed better insight into the nature of these relationships leading to practical application of our findings that can be used to address the ongoing issue of rising antimicrobial resistance.. My work has been supported, over the years, with competitive funding from both the public and private sectors.

Positions and Honors:
Faculty Appointments

1973-89University of Utah Colleges of Pharmacy and Medicine
(last rank: Professor of Clinical Pharmacy and Pediatrics; tenured)
1981 University of California at San Francisco (Visiting Professor)
1989-92Univerisity of Houston College of Pharmacy (tenured Professor)
Baylor College of Medicine (Adjunct Associate Professor of Pediatrics)
1992-presentMedical University of South Carolina, Colleges of Pharmacy and Medicine
(tenured Professor)

Administrative Appointments
1990-2Vice Chair, Department of Pharmacy Practice, University of Houston
1992-5Vice Chair for Research, Department of Hospital Pharmacy Practice and
Administration, Medical University of South Carolina
2003-presentChair, Department of Clinical Pharmacy and Outcome Sciences, Medical University of South Carolina

Honors and Awards

  • Rho Chi Society (Pharmacy Honor Society), 1974
  • Lederle Faculty Award, 1975
  • Award for Achievement in the Professional Practice of Hospital Pharmacy (American Society of
    Hospital Pharmacists Research and Education Foundation), 1980
  • Fellow, American College of Clinical Pharmacy, 1987
  • American College of Clinical Pharmacy – Merck Sharp & Dohme Infectious Disease Research
    Fellowship (Preceptor), 1991-2
  • American College of Clinical Pharmacy – Miles Infectious Disease Research Fellowship (Preceptor), 1995-6
  • Phi Lambda Sigma (Pharmacy Leadership Society); elected to membership, 2002
  • Fellowship, Infectious Diseases Society of America, 2008

Selected peer-reviewed publications (in chronological order)

  1. Bosso JA, Townsend PL, Herbst JJ, Matsen JM. Pharmacokinetics and dosage requirements of netilmicin in cystic fibrosis patients. Antimicrob Agents Chemother 1985;28:829-31.
  2. Douglas JM, Judson FN, Levin MJ, Bosso JA, Spruance SL et al. A placebo controlled trial of topical 8% arildone cream early in recurrent genital herpes. Antimicrob Agents Chemother 1986;29:464-7.
  3. Bosso JA, Black PG, Matsen JM. Efficacy of aztreonam in pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis 1987;6:393-7.
  4. Bosso JA, Black PG, Matsen JM. Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult cystic fibrosis patients. Am J Med 1987;82(Suppl 4A):180-4.
  5. Bosso JA, Black PG. A controlled trial of aztreonam vs. tobramycin plus azlocillin for acute pulmonary exacerbations of cystic fibrosis. Pediatr Infect Dis J 1988;7:171-6.
  6. Bosso JA, Liptak CA, Seilheimer DK, Harrison GM. Toxicity of colistin in cystic fibrosis patients. DICP. Ann Pharmacother 1991;25:1168-70.
  7. Huls CE, Prince RA, Seilheimer DK, Bosso JA. Pharmacokinetics of cefepime in cystic fibrosis patients. Antimicrob Agents Chemother 1993;37:1414-6.
  8. Annaissie EJ, Kontoyiannis DP, Huls C, Vartivarian SE,Karl C, Prince RA, Bosso JA, Bodey GP. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. J Infect Dis 1995;172:599-602.
  9. Bosso JA, Bonapace RC, Flume PA, White RL. A pilot study of the efficacy of constant infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis. Pharmacotherapy 1999;19:620-6.
  10. Bosso JA, Flume PA, Gray SL. Linezolid pharmacokinetics in adult patients with cystic fibrosis.
    Antimicrob Agents Chemother 2004;48:281-4.
  11. Bosso JA, Mauldin PD. Assessment of effects of fluoroquinolone formulary changes on Gram-negative susceptibility and MRSA isolation rates using interrupted time series analysis, Antimicrob Agents Chemother 2006;50:2106-12.
  12. Mauldin PD, Salgado CD, Durkalski VL, Bosso JA. Nosocomial infections due to Methicillin-resistant S. aureus and Vancomycin-resistant Enterococcus: Relationships with antibiotic use and cost drivers. Ann Pharmacother 2008;42:317-26.
  13. Salgado CD, Mauldin PD, Bosso JA. Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. Am J Infect Control, 2009;37:458-64.
  14. Mauldin PD, Salgado CD, Hansen IS, Durup DT, Bosso JA. Attributable hospital cost and length of stay associated with healthcare associated infections caused by antibiotic-resistant, Gram-negative bacteria. Antimicrob Agents Chemother 2010;54:109-15.
  15. Church EC, Mauldin PD, Bosso JA. Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: An interrupted time series analysis. Infect Control Hosp Epidemiol 2011;32:400-1.
  16. Bosso JA, Nappi J, Rudisill C, Wellein M, Bookstaver PB, Swindler J, Mauldin PD. The relationship between vancomycin trough concentrations and nephrotoxicty: A prospective, multi-center trial. Antimicrob Agents Chemother 2011;55:5475-9. DOI: 10.1128/AAC.00168-11
  17. Bosso JA, Sieg A, Mauldin PD. A comparison of hospital-wide and custom antibiograms for clinical isolates of Pseudomonas aeruginosa (in press).
  18. Hurst JM, Bosso JA. Antimicrobial stewardship in the management of community-acquired pneumonia. Curr Opin Infect Dis (in press).

Research Support:
Recently Completed

  • Safety of High-Concentration Vancomycin for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections, 2008-present. Goal: prospectively examine relationship between high dose vancomycin and incidence of nephrotoxicity. Principal investigator.


  • Impact of MRSA Decolonization Therapy on MRSA Infection & Transmission (1 R01 HS018954-01A1). Co-investigator: 5%, (Arch Mainous, PI), AHRQ 7/1/2011—6/30/2016. $2,396,266
  • Assessment of the Relationship between Patterns of Antibiotic Use and Pseudomonas aeruginosa susceptibility over time in Pediatric Patients (not funded).
  • Assessment of the Relationship between Patterns of Antibiotic Use and E. coli and K. pneumoniae susceptibility over time (not funded).

Susan L. Davis, PharmD
Associate Professor (Clinical) of Pharmacy Practice; Wayne State University
Infectious Diseases Pharmacy Specialist, Henry Ford Hospital
Click here for Biographical Sketch:

Education / Training :

University of Michigan College of Pharmacy
Ann Arbor, MI
Detroit Receiving Hospital
Detroit, MI
Residency2003PGY1 pharmacy practice
The Anti-Infective Research Laboratory, Wayne State University, Detroit, MIFellowship2005Infectious Diseases Outcomes Research
Wayne State University School of Medicine
Detroit, MI
n/a2003-5courses completed in biostatistics
and epidemiology
University of Michigan School of Public Health
Graduate Summer Session
Ann Arbor, MI
n/a2004-5courses completed: clinical trial design and analysis; pharmacoepidemiology

Personal Statement:
The MAD-ID Research Network offers an opportunity for antimicrobial stewardship practitioners to engage in collaborative research that promotes the optimal use of antimicrobial agents. Prudent use of antimicrobial therapy has been shown to be a key factor in improving patient safety and outcomes while reducing cost and curbing the spread of antimicrobial resistance. Innovative approaches to antimicrobial stewardship are needed to develop generalizable and sustainable practice models to be used across a variety of healthcare settings. The diversity and enthusiasm of the MAD-ID research network provides a unique collaboration to explore these practices. In my dual appointment with Wayne State University and with Henry Ford Hospital, my primary job responsibilities include education and research related to anti-infective pharmacotherapy with particular focus on antimicrobial stewardship and outcomes of healthcare-associated infection. I have previously worked with many members of the MAD-ID group, and I look forward to our continued partnerships.

Positions and Honors:
Employment and Recognition

2005Clinical Associate Professor of Pharmacy Practice, Wayne State University
2005Infectious Diseases Pharmacy Specialist, Henry Ford Hospital
2008American Society of Health-System Pharmacists Foundation New Preceptor of the Year Award
2008Co-director, Infectious Diseases Outcomes Research Fellowship Program, Anti-Infective Research Laboratory, Wayne State University. (Fellows mentored: R Bhan, R Kullar, A Casapao)
2011Program Director, Antimicrobial Stewardship Pharmacy Fellowship Program, Wayne State University and Henry Ford Hospital (Fellows mentored: J Carreno)
2012Society of Infectious Diseases Pharmacists Outstanding Clinical Practice Award

Other Experience and Professional Memberships
1998-currentMember, American Society of Health-System Pharmacists (ASHP)
2010-12, ASHP Foundation Residency Excellence Awards Committee
2001-currentMember, American College of Clinical Pharmacy (ACCP)
2005, 2006, ACCP Infectious Diseases PRN Election Committee
2012-13, ACCP Recognition Awards Committee
2002 - 2010Member, Southeastern Michigan Society of Health-System Pharmacists (SMSHP)
2004-7, Awards Committee Chair
2007-9, Board Member-at Large

2002-currentMember, Michigan Pharmacists Association (MPA)
2003-currentMember, American Society for Microbiology (ASM)
2003-currentMember, Infectious Diseases Society of America (IDSA)
2003-currentMember, Society of Infectious Diseases Pharmacists (SIDP)
2006-7, Membership Committee
2007-8, Recognition Awards Committee
2008 – present, Program committee; Vice-Chair, 2010-12, Chair, 2013
2012Editorial Board Member, Pharmacotherapy
2012-2013Grant Review Panel, ASHP Foundation, Medication Complexity Score

Selected peer-reviewed publications (in chronological order)

  1. Chambers RM, Davis SL. Expanding the reach of antimicrobial stewardship. Pharmacotherapy, February 2013.
  2. Kullar R, Davis SL, Kaye KS, Levine DP, Pogue, JM, Rybak MJ. Implementation of an antimicrobial stewardship guideline for optimal therapy of MRSA bacteremia with elevated vancomycin MIC. Pharmacotherapy 2013; 33(1):3-10.
  3. Kullar R, Davis SL, Taylor TN, Kaye KS, Rybak MJ. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort.Pharmacotherapy 2012; March 2012: 195-201.
  4. Kullar R, Leonard SN, Davis SL, Delgado, G Jr, Pogue JM, Wahby KA, Falcione B, Rybak MJ. Validation of the Effectiveness of a Vancomycin Nomogram in Achieving Target Trough Concentrations of 15–20 mg/L Suggested by the Vancomycin Consensus Guidelines. Pharmacotherapy. 2011;5:441-8.
  5. Kullar R, Davis SL, Levine DP, Zhao JJ, Crank C, Segreti J, Sakoulas G, Cosgrove SE, Rybak MJ. A Large Multi-Center Study of High-Dose Daptomycin for Complicated Gram-Positive Infections. Pharmacotherapy June 2011.
  6. Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of Vancomycin Exposure on Outcomes in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets. Clin Infect Dis. 2011 Apr;52(8):975-81. *2012 SIDP Impact Paper of the Year*
  7. Toth N, Chambers RM, Davis SL. Implementation of a care bundle for antimicrobial stewardship. AJHP 2010;67:746-9.
  8. Winegardner M, Davis SL, Szandzik EG, Kalus JK. Non-traditional PGY1 residency training program. AJHP 2010;67:366-70.
  9. Davis SL, Rybak MJ, Hall LM, Delgago G, Rose W, Wilson RF, McKinnon PS. Clinical and economic outcomes of daptomycin versus vancomycin for complicated skin and skin structure infections. Pharmacotherapy 2007;27(12):1611-1618.
  10. Davis SL, Perri MB, Donabedian SM, Manierski C, Singh A, Vager A, Haque NZ, Spiers K, Muder RR, Robinson-Dunn B, Hayden MK, Zervos MJ. Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus. Journal of Clinical Microbiology, 2007; 45(6):1705-1711. PMCID: PMC1933099
  11. Davis SL, Vazquez JA, McKinnon PS. Epidemiology and outcomes of patients with albicans versus non-albicans candidemia at an urban tertiary care center. Annals of Pharmacotherapy, 2007;41:568-573.
  12. Davis SL, Rybak MJ, Amjad M, Kaatz GW, McKinnon PS. Characteristics of patients with healthcare-associated SCCmec IV methicillin-resistant Staphylococcus aureus. Infection Control and Hospital Epidemiology 27(10):1025-31, October 2006.
  13. Davis SL, Delgado G Jr, McKinnon PS. Pharmacoeconomic considerations with IV to PO moxifloxacin for community acquired pneumonia. Clin Infect Dis 41 (Suppl2):S135-43, July 2005.

Research Support:

  • American Society of Health System Pharmacists/ASHP Foundation Pharmacy Practice Model Initiative. Carreno JJ, Chambers RM, Kilgore P, Weinmann A, Bloome M, Centi A, Rodriguez J, Davis SL (PI). “Antimicrobial stewardship provided through novel approaches to optimize pharmacists workflow (Stewardship-NOW)” Role: Primary Investigator
  • Advancing Science through Pfizer Investigator Research. (Martin E, PI) “Outcomes following Linezolid Therapy in Complicated Skin and Soft Tissue Infections: A Multi-Center Retrospective Study” Role: Co-Investigator
  • ASHP Foundation Pharmacy Residency Practice Based Research Grants 2012. Dumkow, L, Chambers R, MacDonald N, Davis SL Culture Shock: Impact of a Pharmacist-run Antimicrobial Culture Follow-up Program in the Emergency Department. Role: Senior Investigator.

Completed: (past 3 years)

  • Cubist Pharmaceuticals, (Rybak MJ, PI); April 2010 – 2012. Multicenter study of high dose daptomycin for enterococcal infections. Role: Co-Investigator
  • Cubist Pharmaceuticals, (Rybak MJ, PI) June 2009 – 2011. Evaluation of a Clinical Pathway for the Treatment of MRSA Bacteremia with MIC of >1mg/L to Vancomycin. Role: Co-Investigator
  • Astellas Pharmaceuticals, (Rybak MJ, PI), Completed March 2011. Cost and clinical implications of targeting higher vancomycin trough concentrations in a matched cohort of patients. Role: Co-Investigator
  • Cubist Pharmaceuticals, (Rybak MJ, PI) Completed January 2011. A Large Case Series of High-Dose Daptomycin Therapy. Role: Co-Investigator
  • Cubist Pharmaceuticals, (Rybak MJ, PI) Completed December 2010. Evaluation of a Vancomycin Nomogram to Achieve Target Troughs of 15 to 20 ml/L. Role: Co-Investigator

Marc Howard Scheetz
Associate Professor of Pharmacy and Infectious Diseases Pharmacist
Click here for Biographical Sketch:

Education / Training :

Butler University College of Pharmacy and Health Sciences, Indianapolis, INPharmD05/2003Clinical Pharmacy
Northwestern Memorial Hospital, Chicago, ILResidency06/2004Pharmacy Practice
Northwestern Memorial Hospital, Chicago, ILFellowship06/2006Anti-Infective Pharmacodynamics and Outcomes
Northwestern University, Chicago, ILMSc05/2007Clinical Investigation

Personal Statement:

I have the expertise, leadership and motivation necessary to successfully carry out the proposed work. My high level training has prepared me to be successful with the methods proposed here. I have a broad background in clinical and translational research methodologies in the area of infectious diseases pharmacotherapy, with specific training and expertise in key research areas for this application. As a postdoctoral fellow at Northwestern Memorial Hospital, I carried out clinical and translational research in the area of anti-infective toxicity and efficacy. To improve my study methodologies, I obtained a Master of Science in Clinical Investigation at Northwestern University. As PI or Co-Investigator on several previous university- and non-federally-funded grants, I laid the groundwork for the proposed research by developing and applying novel methodologies for understanding drug exposure and toxicity relationships. I successfully administered these projects (e.g. staffing, research protections, budget) and produced several peer-reviewed publications from each venture. As a result of these previous experiences, I am aware of the importance of frequent communication among project members and of constructing a realistic research plan, timeline, and budget. In summary, I am an independent biomedical researcher, and I have a demonstrated record of successful and productive research projects in the area of clinical and translational drug toxicity modeling. My expertise and experience have prepared me to lead the proposed project, and I look forward to having the opportunity to do so.

Positions and Employment:

2006-Infectious Diseases Pharmacist, Northwestern Memorial Hospital, Chicago, IL
2007-2012Assistant Professor of Pharmacy Practice, Midwestern University, Downers Grove, IL
2012-Associate Professor of Pharmacy Practice with Tenure, Midwestern University, Downers Grove, IL

Other Experience and Professional Memberships:
2004-Member, Society of Infectious Diseases Pharmacists
2004-Member, American College of Clinical Pharmacy
2012-13, ACCP Recognition Awards Committee
2007-Member, American Society of Microbiology
2011-Clinical Medicine and Research, editorial board member
2011-ZonMw (The Netherlands Organisation for Health Research and Development)-Priority Medicines Antimicrobial Resistance Programme, reviewer
2012-Center for Scientific Review, National Institutes of Health, early career reviewer

Reviewer for Journals (active status):
Journal of Antimicrobial Chemotherapy, 2007- ;Pharmacotherapy, 2007-; Antimicrobial Agents and Chemotherapy, 2010- ; CHEST, 2010- ; Clinical Infectious Diseases, 2011-

Butler University, Deans List, 1997-2003; Butler University Academic Scholarship,1997-2003; Rudolph J. Roehl Scholarship, 1999; A.J.W. LeBien Scholarship, 2000; Phi Kappa Psi Summerfield Scholarship,2000; Butler University Top 100 Students award, 2001; Phi Kappa Psi Founders’ Fellowship graduate study scholarship, 2001; McKesson HBOC pharmacy scholarship, 2001-2003; Cum Laude, High Honors in Pharmacy (highest GPA based award), 2003; IDSA Travel Grant for excellent research among fellows-in-training, 2004-05; MWU Teacher of the Year Runner-up, P-3 Class, 2007-2010; Society of Infectious Diseases Pharmacists, Young Investigator of the year, 2012.

Selected peer-reviewed publications (Selected from 56 peer-reviewed publications)
Most relevant to the current application (in chronological order)

  1. Defife R, Scheetz MH, Feinglass JM, Postelnick MJ, Scarsi KK. Effect of differences in MIC values on clinical outcomes in patients with bloodstream infections caused by gram-negative organisms treated with levofloxacin. Antimicrob Agents Chemother. 2009;53(3):1074-9. PMCID: PMC2650520.
  2. Scheetz MH, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, et al. Morbidity associated with Pseudomonas aeruginosa bloodstream infections. Diagn Microbiol Infect Dis. 2009;64(3):311-9. PMCID: PMC2693471.
  3. Patel N, Scheetz MH, Drusano GL, Lodise TP. Determination of antibiotic dosage adjustments in patients with renal impairment: elements for success. J Antimicrob Chemother. 2010;65(11):2285-90. PMCID: 20736235.
  4. Patel N, Scheetz MH, Drusano GL, Lodise TP. Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients. Antimicrob Agents Chemother. 2010;54(1):460-5. PMCID: PMC2798531.
  5. Steadman E, Raisch DW, Bennett CL, Esterly JS, Becker T, Postelnick M, Scheetz MH. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother. 2010;54(4):1534-40. PMCID: PMC2849391.

Additional recent publications of importance to the field (in chronological order).

  1. Scarsi KK, Feinglass JM, Scheetz MH, Postelnick MJ, Bolon MK, Noskin GA. Impact of inactive empiric antimicrobial therapy on inpatient mortality and length of stay. Antimicrob Agents Chemother. 2006;50(10):3355-60. PMCID: PMC1610056.
  2. Scheetz MH, Hurt KM, Noskin GA, Oliphant CM. Applying antimicrobial pharmacodynamics to resistant Gram-negative pathogens. Am J Health Syst Pharm. 2006;63(14):1346-60.
  3. Scheetz MH, Knechtel SA, Malczynski M, Postelnick MJ, Qi C. Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. Antimicrob Agents Chemother. 2008;52(6):2256-9. PMCID: PMC2415807.
  4. Scheetz MH, Esterly JS, Malczynski M, Postelnick M, Qi C. Impact of dissimilar susceptibility breakpoints for doripenem on susceptibility and carbapenem discordance for Pseudomonas aeruginosa. Diagn Microbiol Infect Dis. 2009;64(4):465-7. PMCID: PMC2798531.
  5. Trifilio SM, Yarnold PR, Scheetz MH, Pi J, Pennick G, Mehta J. Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2009;53(5):1793-6. PMCID: PMC2681520.
  6. Esterly JS, Qi C, Malczynski M, Scheetz MH. Predictability of doripenem susceptibility in Acinetobacter baumannii isolates based on other carbapenem susceptibilities and bla OXA gene status. Pharmacotherapy. 2010;30(4):354-60. PMCID: PMC3019689
  7. Scheetz MH, Knechtel SA, Postelnick MJ, Malczynski M, Qi C. Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility. Pharmacotherapy. 2010;30(12):1221-8. PMCID: PMC3118644
  8. Trifilio SM, Scheetz MH, Pi J, Mehta J. Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring. Bone Marrow Transplant. 2010;45(8):1352-6. PMCID: PMC2849391
  9. Esterly JS, Griffith M, Qi C, Malczynski M, Postelnick MJ, Scheetz MH. Impact of carbapenem resistance and receipt of active antimicrobial therapy on clinical outcomes of Acinetobacter baumannii bloodstream infections. Antimicrob Agents Chemother. 2011;55(10):4844-9. PMCID: PMC3186964
  10. Gorski E, Esterly JS, Postelnick M, Trifilio S, Fotis M, Scheetz MH. Evaluation of hepatotoxicity with off-label oral-treatment doses of voriconazole for invasive fungal infections. Antimicrob Agents Chemother. 2011;55(1):184-9. PMCID: PMC3019689

Research Support:
Ongoing Research Support

  1. Society of Infectious Diseases Pharmacists (10/2011-4/2013)
    Young Investigator Research Award. Clinical outcomes of KPC bloodstream infections.
    This grant aims to classify the clinical and microbiologic virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae by simultaneously assessing virulence in patients with bloodstream infections and separately employing in an in-vivo Galleria mellonella host model.
    Role: PI
  2. Midwestern University Chicago College of Pharmacy (7/2010-12/2012)
    Assessment of Correlation between Virulence and Linezolid Resistance, Outbreak Status, and Species of Vancomycin Resistant Enterococci.
    The aim of this grant is to classify the virulence of clinical strains of Enterococci in a validated laboratory model with Galleria mellonella.
    Role: PI
  3. Midwestern University Chicago College of Pharmacy (7/2009-12/2012)
    Virulence of Acinetobacter baumannii containing BLAOXA genes.
    The aim of this grant is to classify the virulence of clinical strains of A. baumannii in a validated laboratory model with Galleria mellonella.
    Role: PI
  4. Midwestern University Chicago College of Pharmacy (07/08- current)
    The Midwestern University CCP Student Research Awards.
    The aim of this grant is to fund a PharmD candidate for a summer research experience. Efforts have evaluated the clinical outcomes associated with the concomitant use of ceftriaxone and calcium, the clinical virulence of A. baumannii according to the presence of carbapenemase genes, and the clinical outcomes of subjects receiving treatment for Gram negative bloodstream infections with elevated minimum inhibitory concentrations to carbapenems.
    Role: PI

Completed Research Support (last 3 years)

  1. Society of Infectious Diseases Pharmacists (07/08- 07/10)
    Young Investigator Research Award. Clinical outcomes of KPC bloodstream infections.
    This grant aims to classify the clinical and microbiologic virulence of Klebsiella pneumoniae producing carbapenemase Klebsiella pneumoniae by simultaneously assessing virulence in patients with bloodstream infections and separately employing in an in-vivo Galleria mellonella host model.
    Role: PI
  2. Midwestern University Chicago College of Pharmacy (10/07-10/2009)
    Incidence of Genotypically Proven Linezolid Resistance in Vancomycin Resistant Enterococci.
    The aim of this grant is to classify genotypically proven linezolid resistance as a function of time while assessing antimicrobial use of linezolid over the same time period.
    Role: PI